We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas

Dasatinib may be an active agent in assorted indolent sarcomas. The impact of endpoint selection, well‐defined cohorts, and responses (Choi criteria vs Response Evaluation Criteria in Solid Tumors) are discussed. See also pages 90‐7.

Detalles Bibliográficos
Autores principales: Villalobos, Victor M., Hoffner, Brianna, Elias, Anthony D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215314/
https://www.ncbi.nlm.nih.gov/pubmed/27696384
http://dx.doi.org/10.1002/cncr.30377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215314/
https://www.ncbi.nlm.nih.gov/pubmed/27696384
http://dx.doi.org/10.1002/cncr.30377

Ejemplares similares